← SynDRA
DARUNAVIR
SynDRA canonical compound SYN0005272 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CYP3A4 |
|---|
| Mechanism of action | HIV protease inhibitor |
|---|
| Indication | human immunodeficiency virus (HIV-1) |
|---|
| Disease area | infectious disease |
|---|
All known targets
- CYP3A4
- ABCB1
- CYP3A5
- HIV PR
- HIV-1 protease
- gag-pol
- pol
- protease
Mechanisms of action (all sources)
- protease inhibitor
- Modulator
- pol INHIBITOR
Drug classes
- HIV Protease Inhibitors
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiviral Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Viral Protease Inhibitors
- Protease Inhibitor
- Cytochrome P450 2D6 Inhibitors
- Cytochrome P450 3A Inhibitors
ATC classes
- J05A · DIRECT ACTING ANTIVIRALS
Cross-references
Synonyms
- darunavir ethanolate
- prezista
- TMC 114
- darunavir ethnolate
- (-)-darunavir
- TMC-114
- TMC-41629
- TMC114
- UIC-94017
- UIC-940T
- Darunavir component of prezcobix
- Darunavir component of symtuza
- Darunavir krka
- Darunavir krka d.d.
- Darunavir viatris (previously darunavir mylan)
- Prezista
- UIC 94017
- Darunavirum
- Darunavirum [INN-Latin]
- UNII-YO603Y8113
- AIDS073035
- CHEMBL1323
- (3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE
- CHEBI:367163
- Darunavir-d9
- YO603Y8113
- (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ((2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-yl)carbamate
- NCGC00168773-01
- (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
- Darunavir [USAN]
- Prezista(TM)
- UIC-96017
- Darunavir (USAN/INN)
- Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester
- {(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
- [(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester
- N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(330)oct-2-yloxy)carboxamide
- [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
Reported adverse events
- Rash
- Hepatotoxicity
- Headache
- Fatigue
- Nausea
- Rhabdomyolysis
- Toxic epidermal necrolysis
- Asthenia
- Dyspepsia
- Vomiting
- Crystal nephropathy
- Abdominal distension
Look up DARUNAVIR in the interactive SynDRA portal →